Metapopulation dynamics and spatial heterogeneity in cancer

With the advent of drugs targeting specific molecular defects in cancerous cells [Gorre, M. E., et al. (2001) Science 293, 876–880], it is important to understand the degree of genetic heterogeneity present in tumor cell populations and the rules that govern microdiversity in human cancer. Here, we first show that populations with different genotypes in genes influencing cell growth and programmed cell death coexist in advanced malignant tumors of the colon, exhibiting microsatellite instability. Detailed, physical mapping of the diverse populations shows them to be arranged in small, intermingling areas, resulting in a variegated pattern of diversity. Using computational modeling of the experimental data, we find that the coexistence between similar competitors is enhanced, instead of deterred, by spatial dynamics [Hanski, I. (1999) Metapopulation Dynamics (Oxford Univ. Press, New York)]. The model suggests a simple and plausible scenario for the generation of spatial heterogeneity during tumor progression. The emergence and persistence of the patterns of diversity encountered in the tumors can be generated without a need to invoke differences in mutation rates, neutrality of interactions, or separated time scales. We posit that the rules that apply to spatial ecology and explain the maintenance of diversity are also at work in tumors and may underlie tumor microheterogeneity.

[1]  W. Gardner,et al.  Carcinogenesis , 1961, The Yale Journal of Biology and Medicine.

[2]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[3]  R. Kerbel,et al.  Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. , 1988, Cancer research.

[4]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[5]  C. James,et al.  Molecular genetics of human cancer predisposition and progression. , 1991, Mutation research.

[6]  AC Tose Cell , 1993, Cell.

[7]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[8]  R. Derynck,et al.  Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. , 1993, Science.

[9]  R. Lenski,et al.  Evidence for multiple adaptive peaks from populations of bacteria evolving in a structured habitat. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Genes, chromosomes & cancer , 1995 .

[11]  A. Feinberg,et al.  Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression , 1995, Nature Medicine.

[12]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[13]  Luzhe Sun,et al.  Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells (*) , 1995, The Journal of Biological Chemistry.

[14]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[15]  G. Thomas,et al.  BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. , 1997, Cancer research.

[16]  S. Korsmeyer,et al.  Bax suppresses tumorigenesis and stimulates apoptosis in vivo , 1997, Nature.

[17]  I. Hanski Metapopulation dynamics , 1998, Nature.

[18]  Michael Travisano,et al.  Adaptive radiation in a heterogeneous environment , 1998, Nature.

[19]  Ricard V. Solé,et al.  Modeling spatiotemporal dynamics in ecology , 1998 .

[20]  R. Dickman,et al.  Nonequilibrium Phase Transitions in Lattice Models , 1999 .

[21]  Y. Yatabe,et al.  Frameshift mutations in TGFbetaRII, IGFIIR, BAX, hMSH3 and hMSH6 are absent in lung cancers. , 1999, Carcinogenesis.

[22]  D. Tilman Diversity by Default , 1999, Science.

[23]  M. Slattery,et al.  Regional reproducibility of microsatellite instability in sporadic colorectal cancer , 1999, Genes, chromosomes & cancer.

[24]  R. Hruban,et al.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.

[25]  V. Moreno,et al.  Standardized approach for microsatellite instability detection in colorectal carcinomas. , 2000, Journal of the National Cancer Institute.

[26]  John Calvin Reed,et al.  Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Eckstein,et al.  Mutations associated with microsatellite unstable colorectal carcinomas exhibit widespread intratumoral heterogeneity , 2000, Genes, chromosomes & cancer.

[28]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[29]  F. Taddei,et al.  Costs and Benefits of High Mutation Rates: Adaptive Evolution of Bacteria in the Mouse Gut , 2001, Science.

[30]  P. Peltomäki,et al.  Deficient DNA mismatch repair: a common etiologic factor for colon cancer. , 2001, Human molecular genetics.

[31]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.